Therapeutic Solutions International and Campbell Neurosciences Publish on Nutritional Modulation of the Indolamine 2,3 Dioxygenase Pathway as a Non-Toxic Means of Addressing Depression

Rhea-AI Summary

Therapeutic Solutions International, Inc. (TSOI) announced a publication with Campbell Neurosciences and academic institutions regarding the modulation of the indolamine 2,3 dioxygenase pathway in depression by QuadraMune®, a patented nutraceutical. The publication highlights the potential of QuadraMune® in treating major depressive disorder, addressing the 'Silent Epidemic' of depression resistant to conventional medication.

Patented QuadraMune® Product Shown to Modulate Biochemical Pathway Associated with Major Depressive Syndrome

ELK CITY, Idaho--(BUSINESS WIRE)-- Therapeutic Solutions International, Inc. (TSOI), announced today a publication with Campbell Neurosciences and several academic institutions describing the importance of the indolamine 2,3 dioxygenase pathway in depression, as well as modulation of this pathway by QuadraMune®, a multi-patented nutraceutical that is commercially available.

The publication is freely available at PsyArXiv Preprints | Modulation of the Indolamine 2,3 Dioxygenase Pathway as a Means of Treating Depression (osf.io).

“QuadraMune® was developed as an immune stimulator for the prevention and treatment of COVID-19 and was granted several patents for this indication^1,2. Subsequently, the science behind QuadraMune® was validated by numerous independent institutions^3,4,” said Thomas Ichim, Ph.D., President, and Chief Executive Officer of Campbell Neurosciences and Board Member of Therapeutic Solutions International. “Through its ability to suppress activation of the indolamine 2,3 dioxygenase pathway, as well as preliminary data reported in our publication, we are eager to explore the utility of this approach in the area of major depressive disorder”.

Campbell Neurosciences is a subsidiary of Therapeutic Solutions International and has developed a blood-based test for suicidal propensity, as well as several therapeutic approaches to immunologically address mental health.

“Depression resistant to conventional medication is considered to be a “Silent Epidemic” and affects up to one of three patients⁵,” said Noelle Ramos, first author of the publication and consultant to the Company. “Through combining the cutting-edge immunological experiences of Dr. Ichim, as well as the deep neurology and medical knowledge of the other coauthors, I am confident that this paper is a first step in shifting our perception of depression from a strictly biochemical disorder to a more immunological associated condition.”

“QuadraMune® is one of several approaches using science-based nutraceuticals developed by the Company,” said Timothy Dixon, President and CEO of Therapeutic Solutions International. “While we are usually reporting on medical advancements accomplished by our regenerative medicine division, the fact that we have products commercialized is an interesting aspect of our company that I suspect will be receiving more attention as the state of our progress advances. The caliber of the current paper’s co authors we see as a positive signal”.

About Therapeutic Solutions International, Inc.

Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is www.therapeuticsolutionsint.com.

1 Therapeutic Solutions International Granted Landmark United States Patent on Ability of QuadraMune® Nutraceutical to Repair Injured Brains | Business Wire
2 Therapeutic Solutions gets 2nd US patent on QuadraMune for COVID-19 | Seeking Alpha
3 John Hopkin’s University Publishes Efficacy of QuadraMune™ Ingredient Sulforaphane at Inhibiting Coronavirus in Laboratory – Bloomberg
4 Therapeutic Solutions International Discusses Claims of Possible COVID-19 Suppressive Activity of QuadraMune™ Ingredients by Independent Universities Made After Patent Filing (prnewswire.com)
5 The Silent Epidemic of Treatment-Resistant Depression | Psychology Today

View source version on businesswire.com: https://www.businesswire.com/news/home/20231127794359/en/

Timothy G. Dixon

ir@tsoimail.com

Source: Therapeutic Solutions International, Inc.

FAQ

What did Therapeutic Solutions International, Inc. (TSOI) announce?

TSOI announced a publication with Campbell Neurosciences and academic institutions regarding the modulation of the indolamine 2,3 dioxygenase pathway in depression by QuadraMune®, a patented nutraceutical.

What is the significance of the publication?

The publication highlights the potential of QuadraMune® in treating major depressive disorder, addressing the 'Silent Epidemic' of depression resistant to conventional medication.

What is QuadraMune®?

QuadraMune® is a multi-patented nutraceutical developed as an immune stimulator for the prevention and treatment of COVID-19, with potential application in treating major depressive disorder.

Who are the key individuals involved in the publication?

Key individuals include Thomas Ichim, Ph.D., President and CEO of Campbell Neurosciences and Board Member of Therapeutic Solutions International, and Noelle Ramos, first author of the publication and consultant to the Company.

What is the goal of the publication?

The publication aims to shift the perception of depression from a strictly biochemical disorder to a more immunologically associated condition, exploring the utility of QuadraMune® in the area of major depressive disorder.